Effects of processed low-protein brown rice on patients with chronic kidney disease

Chronic kidney disease (CKD) disrupts the gut microbiome in ways that may accelerate kidney damage and cause bowel problems like constipation. Researchers in Japan developed a fermented, low-protein brown rice (LPBR) — an unpolished whole grain — and tested whether eating it daily could improve kidney function, bowel habits, and gut bacteria composition in people with moderate-to-severe CKD. Over three months, 29 outpatients with stage 3–4 CKD ate LPBR as a dietary intervention. The study found that constipation scores improved significantly, urinary protein excretion fell, and levels of a beneficial gut metabolite called acetic acid rose. The gut bacterium Bifidobacterium longum also trended upward, and its increase was correlated with both better bowel scores and higher acetic acid levels. Acetic acid, a short-chain fatty acid produced by fiber-fermenting gut bacteria, is thought to support gut barrier integrity and reduce systemic inflammation — both relevant to CKD progression. The results suggest that a simple, culturally accessible whole-food intervention can simultaneously nudge the gut microbiome toward a healthier state and produce measurable clinical benefits in CKD patients.

• Constipation Scoring System (CSS) scores improved significantly after 3 months of LPBR intervention (P = 0.023), indicating meaningful relief of constipation.
• Urinary protein excretion decreased (P = 0.050) and eGFR declined at a reduced rate (P = 0.044), both primary renal outcomes showing a beneficial trend.
• Fecal acetic acid levels increased significantly (P = 0.024); changes in acetic acid were positively correlated with improvements in both eGFR trajectory and Bristol Stool Form Scale scores.
• Bifidobacterium longum abundance trended upward (P = 0.094, not reaching conventional significance), and its change correlated positively with acetic acid increases and improved CSS scores, suggesting a microbiome-metabolite axis underlies the clinical benefit.

This was a 3-month, single-arm (uncontrolled) interventional study conducted at an outpatient nephrology clinic in Japan, enrolling 30 patients with stage 3–4 CKD, of whom 29 completed assessable follow-up. Participants consumed fermented low-protein brown rice (LPBR) as a dietary staple throughout the intervention period. Primary outcomes were changes in urinary protein excretion, eGFR, and defecation condition (CSS and Bristol Stool Form Scale); secondary assessments included fecal short-chain fatty acid quantification and gut microbiota composition by sequencing.

The absence of a control arm means it is impossible to separate the effects of LPBR from regression to the mean, seasonal dietary shifts, or increased clinical attention — a randomized controlled trial is the essential next step. The sample is small (n = 29), ethnically homogeneous (Japanese outpatients), and followed for only three months, limiting generalizability and the ability to detect sustained renal protection or adverse effects. The borderline p-value for Bifidobacterium longum (P = 0.094) and the marginal urinary protein result (P = 0.050) indicate the study is underpowered for firm microbiome conclusions; a larger cohort with shotgun metagenomics and metabolomics would clarify which microbial taxa and metabolic pathways are causally responsible. It also remains unknown whether benefits are attributable to the low-protein content, the whole-grain fermentation products, or the combined effect of both components of LPBR.

This study extends the growing corpus on diet–microbiome–organ-function axes by providing human interventional evidence in a CKD population, a context addressed mechanistically in [§139], which demonstrates how gut microbiota dysbiosis remodels multi-tissue transcriptional landscapes and offers a plausible genomic framework for the systemic effects observed here. The acetic acid–Bifidobacterium axis identified in LPBR-treated patients parallels findings in [§72], where bariatric surgery-driven microbiota remodeling produces short-chain fatty acid shifts linked to metabolic improvement, reinforcing that microbiota-derived SCFAs are a conserved effector pathway across diverse interventions and disease states. The dietary fiber mechanism also parallels [§76], which examines how supplemental dietary fiber alters carbohydrate metabolism and intestinal microbiota in a metabolic disease context, lending comparative support to the idea that fermentable substrates — whether from psyllium, OptiFibre, or whole-grain rice — converge on similar microbial outputs. Against the backdrop of [§87], which maps how gut microbiota regulate systemic inflammatory and anti-inflammatory response syndromes, the renal and bowel improvements seen with LPBR are consistent with attenuation of microbiota-driven pro-inflammatory signaling, though the current study lacks direct inflammatory biomarker data to confirm this mechanism.

• Microbiota remodeling after bariatric surgery: Procedure-specific dynamics and metabolic implications
  Bariatric surgery also drives microbiota remodeling with SCFA shifts and metabolic benefit — comparing procedure-driven versus food-driven microbiome change illuminates whether the LPBR acetic acid effect is truly microbiome-mediated or a direct dietary metabolite effect.
• The Effect of OptiFibre Dietary Fiber on Carbohydrate Metabolism and Intestinal Microbiota Metabolism in Patients With Type 2 Diabetes Mellitus
  Directly parallel design: a dietary fiber intervention assessed for effects on gut microbiota and carbohydrate/metabolic outcomes; comparing effect sizes and microbial taxa changes would help contextualize how whole-grain rice fermentation compares to isolated fiber supplements.
• Gut Microbiota Regulates Systemic Inflammatory Response and Compensatory Anti-Inflammatory Response Syndromes by Targeting PF4+ Macrophages in Acute Pancreatitis
  Provides the inflammatory mechanistic counterpart — examining gut microbiota regulation of systemic inflammatory responses — that this LPBR study lacks direct biomarker evidence for, making the two studies complementary for mechanistic inference.
• Gut Microbiota Dysbiosis Remodels the Multi-Tissue Transcriptional Landscape of the Host
  Offers a multi-tissue transcriptomic view of how microbiota dysbiosis propagates systemic disease, providing a genomic-level framework to interpret why restoring Bifidobacterium longum and acetic acid in CKD might have organ-level consequences beyond the gut.
• Psyllium in Pediatric IBS
  Psyllium fiber intervention in pediatric IBS addresses a different population and condition but tests the same general hypothesis — soluble/fermentable fiber reshapes microbiota and improves gastrointestinal symptoms — enabling cross-condition comparison of fiber-type specificity and microbiome response magnitude.